Province Providing More Reproductive Choice for Women with Access to Mifegymiso

Aug 3, 2017 @ 10:00

Ontario is giving women more choice over their reproductive health by making Mifegymiso, a safe and effective medical alternative to surgical abortion, available at no cost.

Indira Naidoo-Harris, Minister of the Status of Women, on behalf of Dr. Eric Hoskins, Minister of Health and Long-Term Care, was at Women’s Health in Women’s Hands Community Health Centre in Toronto today to announce that, as of August 10, 2017, women with a valid health card and prescription from their doctor or nurse practitioner will be able to get the drug for free at participating pharmacies across the province.

Mifegymiso is taken to medically terminate an early pregnancy. It is a safe, effective and non-invasive alternative to a surgical abortion that women can administer themselves. By making it available at no cost, Ontario is giving women more autonomy around their reproductive health, removing a financial barrier, and increasing equity of access to abortion — particularly in rural and remote areas.

Ontario is increasing access to care, reducing wait times and improving the patient experience through its Patients First: Action Plan for Health Care and OHIP+: Children and Youth Pharmacare – protecting health care today and into the future.


  • Mifegymiso is a combination of two drugs, mifepristone and misoprostol, used to medically terminate early pregnancies (up to 49 days from the start of the last menstrual period).
    It is considered a safe and effective alternative to a surgical abortion.
    Mifegymiso is the only brand of the drug currently approved by Health Canada to be marketed in Canada.
    Prescribers and pharmacists will have access to appropriate training.

One comment

  1. I am just wondering what woman in her right mind would take the protocol mifegymiso and what kind of government would be so cavalier about women’s health to offer it let alone offer it free.

    Reporting on the outcomes of 42,916 Finnish women who underwent chemical or surgical abortion up to 63 days, the following was highlighted. Chemical abortion (Mifegymiso in Canada) had roughly four times the rate of adverse events than surgical abortion for women. 20 out of every 100 women experienced a significant adverse event, about 16 out of 100 hemorrhaged excessively, 7 out of 100 had “tissue” left inside and 6 out of 100 needed surgical re-evacuation of the uterus.

    The report used the tracking system of Finland’s government based medical system to follow the women for 42 days after their induced abortion.

    Mifegymiso is a dangerous cocktail of two drugs designed to kill children in the womb which may cause mayhem for some women.